143 related articles for article (PubMed ID: 23211261)
21. Correlation between prescribing quality and pharmaceutical costs in English primary care: national cross-sectional analysis.
Fleetcroft R; Cookson R; Steel N; Howe A
Br J Gen Pract; 2011 Sep; 61(590):e556-64. PubMed ID: 22152735
[TBL] [Abstract][Full Text] [Related]
22. Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea.
Jeong YJ; Kim H; Baik SJ; Kim TM; Yang SJ; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
J Clin Pharm Ther; 2017 Jun; 42(3):292-300. PubMed ID: 28251662
[TBL] [Abstract][Full Text] [Related]
23. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Hirsch M; O'Donnell JC; Jones P
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
[TBL] [Abstract][Full Text] [Related]
24. Developing prevalence-based prescribing units for analysing variations in general practitioner prescribing: a case study using statins.
Ward PR; Noyce PR; St Leger AS
J Clin Pharm Ther; 2003 Feb; 28(1):23-9. PubMed ID: 12605615
[TBL] [Abstract][Full Text] [Related]
25. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
[TBL] [Abstract][Full Text] [Related]
26. Has cost inhibited the uptake of more potent statins in England?
Chapman SR; Fitzpatrick RW; Aladul MI
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):984-991. PubMed ID: 28612964
[TBL] [Abstract][Full Text] [Related]
27. Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
Valentino M; Al Danaf J; Panakos A; Ragupathi L; Duffy D; Whellan D
Am Heart J; 2016 Nov; 181():130-136. PubMed ID: 27823684
[TBL] [Abstract][Full Text] [Related]
28. Price versus clinical guidelines in primary care statin prescribing: a retrospective cohort study and cost simulation model.
De Zarate MO; Mentzakis E; Fraser SD; Roderick P; Rutter P; Ornaghi C
J R Soc Med; 2022 Mar; 115(3):100-111. PubMed ID: 34793261
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
[TBL] [Abstract][Full Text] [Related]
30. Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study.
de Lusignan S; Belsey J; Hague N; Dhoul N; van Vlymen J
J Public Health (Oxf); 2006 Dec; 28(4):361-9. PubMed ID: 17038329
[TBL] [Abstract][Full Text] [Related]
31. Statin prescribing among hypertensive patients in southwest Nigeria: findings and implications for the future.
Akunne OO; Godman B; Adedapo AD; Truter I; Fadare J
J Comp Eff Res; 2016 May; 5(3):281-8. PubMed ID: 27097045
[TBL] [Abstract][Full Text] [Related]
32. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices.
Hippisley-Cox J; Cater R; Pringle M; Coupland C
BMJ; 2003 Mar; 326(7391):689. PubMed ID: 12663406
[TBL] [Abstract][Full Text] [Related]
33. The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013.
Fuksa L; Vocelka M; Vytrisalova M
Health Policy; 2015 Sep; 119(9):1255-64. PubMed ID: 25929214
[TBL] [Abstract][Full Text] [Related]
34. Cost-efficacy analysis of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors based on results of the STELLAR trial: clinical implications for therapeutic selection.
Chong PH; Varner D
Pharmacotherapy; 2005 Feb; 25(2):270-8. PubMed ID: 15767241
[TBL] [Abstract][Full Text] [Related]
35. [Primary prevention of coronary heart disease? What is cost effective in the clinical practice?].
Kübler W
Z Kardiol; 2005; 94 Suppl 3():III/92-9. PubMed ID: 16258799
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS.
Palmer SJ; Brady AJ; Ratcliffe AE
Int J Clin Pract; 2003 Nov; 57(9):792-800. PubMed ID: 14686571
[TBL] [Abstract][Full Text] [Related]
37. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
38. Potential savings without compromising the quality of care.
Norman C; Zarrinkoub R; Hasselström J; Godman B; Granath F; Wettermark B
Int J Clin Pract; 2009 Sep; 63(9):1320-6. PubMed ID: 19691615
[TBL] [Abstract][Full Text] [Related]
39. Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia.
Demoz GT; Wahdey S; Kasahun GG; Hagazy K; Kinfe DG; Tasew H; Bahrey D; Niriayo YL
BMC Res Notes; 2019 Jul; 12(1):386. PubMed ID: 31288848
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
